Neuroscience Centers Professor and Pharmaceutical Sciences Chair Dr. Paul Lockman will deliver a public lecture on “Disruptive Innovation in Sciences” Thursday, Nov. 2 as part of the 2016-2017 Benedum Lecture Series. The lecture will take place at 4 p.m. in the Health Sciences Fukushima Auditorium, with a public reception to follow.
Lockman’s work on mathematical modelling of drug entry into the brain has led to an understanding of how the specialized system of blood vessels in the brain can prevent chemotherapy from reaching some cancer at effective concentrations. Lockman was named a 2016-2017 Benedum Distinguished Scholar in the Biosciences and Health Sciences category.
W est Virginia University’s Cancer Institute is well-known for its treatment and innovation. Leading the institute is Dr. Richard Goldberg, who has not only established himself as a transformative leader but also a potent researcher and educator. A native of upstate New York, the renowned gastrointestinal cancer expert came to Morgantown about two years ago. Goldberg previously worked at The Ohio State University’s Wexner Medical Center, where he served as the Klotz Family Professor of Cancer Research, the physician‐in‐ chief of the James Cancer Hospital, the associate director of the Ohio State Comprehensive Cancer Center and the acting division director of the Division of Medical Oncology. Before that, he also worked at the University of North Carolina and the Mayo Clinic. Goldberg is one of many world-class physicians recruited by WVU Medicine during the past few years, whose research has resulted in more than 300 peer-reviewed publications, including those in the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology
WVU Heart and Vascular Institute among top sites in innovative pilot study to improve outcomes of heart attacks
The WVU Heart and Vascular Institute was a leading site in a national pilot study assessing a new treatment for patients experiencing a myocardial infarction, or heart attack. The door to unload (DTU) trial was presented yesterday (Oct. 11) as a late breaking clinical trial at the American Heart Association Scientific Sessions 2018.
Surgeons at the WVU Rockefeller Neuroscience Institute have performed the state’s first laser interstitial thermal therapy (LiTT) procedure for drug-resistant epilepsy caused by focal seizures.